# Molecular Assessment Program: MAP

#### Christopher N. Greene, PhD Newborn Screening and Molecular Biology Branch, Division of Laboratory Sciences NCEH, CDC


Friday, March 13<sup>th</sup>, 2015



National Center for Environmental Health

U.S. Centers for Disease Control and Prevention

# **Quality Improvement Cycle**



### NBS Molecular Assessment Program (MAP)

#### Evaluation of molecular newborn screening programs

- Invited site visit of molecular biologists from:
  - CDC's Newborn Screening and Molecular Biology Branch
  - State Public Health Newborn Screening Programs
  - Representatives from Association of Public Health Laboratories

#### Support for newborn screening laboratories

- Non-regulatory review of molecular testing activities
- Guidance for expansion of NBS molecular testing
- Provided at no cost to participating programs

### Why MAP was Developed

#### Gaps in current regulatory guidelines

- No CLIA genetic testing specialty CMS recommends use of general guidelines for high-complexity tests
- Standard regulatory framework does not allow for complexity involved in molecular testing
- Inflexible regulations may prevent use of new technologies

#### What Constitutes a High Complexity Test

- Specialized Knowledge
- Training and Experience
- Reagents and Materials Preparation
- Characteristics of Operational Steps
- Calibration, Quality Control, and PT Materials
- Test System Troubleshooting
- Interpretation and Judgment

Three point scale for each criteria – most molecular 18-21 points

# Why MAP was Developed

- Molecular tests have different quality management requirements
  - DNA extraction
  - PCR amplification common step
  - Cross contamination risks





### **Goals of MAP**

#### NBS Laboratory Support

- Provide molecular testing-specific assistance for NBS laboratories implementing molecular testing
- Guidance for laboratories that are expanding NBS molecular testing
- Mechanism to communicate best practices and strategies for continual laboratory assay quality improvement

### What is the Benefit for NBS Programs?

Consider how to fit molecular testing into a screening program

- Balanced approach:
  - Application needs
  - Available resources



### What is the Benefit for NBS Programs?

#### MAP teams represent a range of molecular NBS experts

- Provide alternate approaches for molecular screening
- Best-practices and ideas for what has worked for other programs
- Help in planning for new molecular screening assays



#### **MAP Activity**

#### Program Site Visits

- 2011: Wisconsin, New York State, Washington State
- 2012: Michigan, Texas
- 2013: Florida, Minnesota, Virginia, Ohio
- 2014: New Jersey, Georgia, Massachusetts, Connecticut
- 2015 (planned): Kentucky, Maryland, Puerto Rico

#### Program Partners

- APHL
- Wisconsin
- New York State
- Washington State
- Michigan
- Texas

### **Basis for Evaluations**

#### Assessment criteria modeled from multiple sources:

- NNSGRC Performance Evaluation Assessment Scheme (PEAS)
- CLIA regulations
- Molecular Pathology Checklist (CAP)
- Standards and Guidelines for Clinical Genetics Laboratories (ACMG)
- Clinical Laboratory Standards of Practice (NYSDOH)
- Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions (MMWR)

### **Professional Guidelines**

### American College of Medical Genetics (ACMG)

Standards and Guidelines for Clinical Genetics Laboratories

- General Standards and Guidelines
- Clinical Biochemical Genetics
- Clinical Molecular Genetics

Disease/Phenotypic-Specific Standards and Guidelines

www.acmg.net – publications



# **Professional Guidelines**

- **Clinical and Laboratory Standards Institute (CLSI)** 
  - MM01-A2: Molecular Diagnostic Methods for Genetic Diseases
  - MM13-A: Collection, Transport, Preparation, and Storage of Specimens for Molecular Methods
  - MM14-A: Proficiency Testing (External Quality Assessment) for Molecular Methods
  - MM17-A: Verification and Validation of Multiplex Nucleic Acid Assays
  - MM19-P: Establishing Molecular Testing in Clinical Laboratory Environments




### **Professional Guidelines**

College of American Pathologists



- Molecular Pathology Accreditation Checklist
- CAP Learning Portal
- Archived webinars and presentations





### **Overview of MAP Site Visits**

#### Pre-visit

Review of written SOP and quality assurance manuals

#### Visit Day 1

- Overview of program and molecular activities
- Assessment of molecular workspace and workflow
- Review of quality assurance, validation documents and molecular reporting

#### Visit Day 2

Exit discussion with program members

#### Post-visit

Written report for program's use

# **MAP Site Visit Agenda**

#### Two – Three Weeks Prior to Site Visit

- Discuss what is the goal for the site visit
- Molecular assay SOPs for review
- Quality Assurance/Management (QA/QM) documents for review

#### **Day Prior to Site Visit**

- Team discusses SOPs and documents to prepare for site visit
- Dinner with hosting laboratory program

# **MAP Site Visit Agenda**

#### Day 1: Morning

- Meet with laboratory members for review of NBS program and current molecular testing activities and future molecular plans
- Program expectations for site visit
- Laboratory observation of molecular procedures

#### Day 1: Afternoon

- SOPs
- Laboratory and molecular-specific QA/QM plans
- Assay validation
- Molecular assay results reports

# **MAP Site Visit Agenda**

#### Day 2: Morning

- Exit discussion with laboratory members
- Observations and recommendations
- Feedback to MAP team



Exit discussions usually finish before noon Additional time can be allocated for specific topics

### **Program MAP Visit Requests**

The NBS Molecular Assessment Program has conducted 10 site visits to state public health newborn screening laboratories. The purpose of NBS laboratory program requesting the site visits have included:

- An overall evaluation of molecular activities
- Suggestions for improving workflow efficiency
- Optimizing the utilization of workspace to reinforce unidirectional workflow
- Planning for implementing new assays
- Preparation for inspections

### **Results from Visits**

- Harmonization of SOPs
- Definition of molecular QA processes
- Modification to workflow
  - Rearrangement of existing laboratory space
  - Acquisition of additional molecular-specific space
- Opportunities for program collaborations
  Increased preparation for annual regulatory inspections

### **Lessons Learned from MAP Visits**

#### Process must be flexible

Every program is unique

#### Molecular-specific QA "Tips and Tricks"

- Numerous valid molecular procedures for a given disorder
- Readily accessible knowledge base for molecular screening is needed

#### CDC and State Cooperation

- Provides a "pulse-point" of molecular needs and challenges
- Opportunities for State-State and Federal-State collaboration

# **Benefits of MAP**

Continual Quality Improvement process for molecular screening

- Address specific concerns of programs
- Recommendations for additional program support
- Provide opportunities for collaboration between public health NBS programs



**MAP Site-Visit Teams** 

Heather Wood (MI) Colleen Stevens (NY) Carlos Saavedra-Matiz (NY) Rachel Lee (TX) Tim Davis (WA) Mei Baker (WI)

#### APHL

Elizabeth Jones Ruhiyyih Degeberg Jelili Ojodu Guisou Piñeryo

#### CDC


Christopher Greene Suzanne Cordovado Stanimila Nikolova Francis Lee Jennifer Taylor Carla Cuthbert

#### APHL's NBS Molecular Subcommittee

### **For More Information on MAP**

For questions about MAP: Christopher Greene cgreene@cdc.gov

For access to the NBS Molecular Resources Website: Guisou Piñeyro guisou.pineyro@aphl.org



http://www.aphl.org/aphlprograms/newborn-screening-and-genetics/molecular/pages/default.aspx

#### For more information please contact Centers for Disease Control and Prevention

1600 Clifton Road NE, Atlanta, GA 30333 Telephone: 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348 Visit: www.cdc.gov | Contact CDC at: 1-800-CDC-INFO or www.cdc.gov/info

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.



National Center for Environmental Health

Division Name in this space